Clinical trials: Stomach Acidity
Healthy Volunteers
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
The purpose of this study is to confirm there is no significant effect of gastric pH changes of famotidine on the drug levels of afimetoran in healthy participants.
- Trial name
- NCT05866627
- Testing
- Famotidine, Afimetoran
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Adults
A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.
This clinical study is designed to evaluate a study medicine called PF-08049820. The main aim is to understand how the body processes this medicine and whether giving it with another medicine, rabeprazole, affects how it behaves.
- Trial name
- NCT07284173
- Testing
- PF-08049820, Rabeprazole
- Where
- 2 sites in China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
The primary objectives of this study are to assess the efficacy of vonoprazan (10 mg and 20 mg once daily [QD]) compared to placebo (QD) in relief of heartburn over 4 weeks in participants with NERD.
- Trial name
- NCT05195528
- Testing
- Vonoprazan
- Where
- 108 sites in United States
- Volunteers
- 776 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease, GERD
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Administration of esomeprazole 20 mg to subjects who still had heartburn after receiving rabeprazole 10 mg once daily for at least 4 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Reflux Esophagitis
- Trial name
- NCT01397084
- Testing
- esomeprazole 20 mg
- Volunteers
- 107 people
- Sponsor
- AstraZeneca
Hypergastrinaemia
Effect of Repeated Doses of YF476 on Stomach Acidity
The objectives of the study were: 1. To show that a single dose of YF476 blocks gastrin receptors in healthy subjects 2. To show that YF476 retains its ability to block gastrin receptors after repeated dosing despite losing its…
- Trial name
- NCT01601405
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Erosive Esophagitis, Reflux Esophagitis
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.
- Conditions
- Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
- Trial name
- NCT00206180
- Testing
- esomeprazole magnesium (oral medication)
- Where
- 39 sites in United States
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Gastritis
Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet
To Evaluate the Efficacy and Safety of CKD-495
- Trial name
- NCT03437785
- Testing
- CKD-495 75mg, CKD-495 150mg, Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg
- Where
- 16 sites in South Korea
- Volunteers
- 250 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy
A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets
This will be a randomized, open-label, single-center, 3-way crossover study in healthy subjects who are confirmed to be Helicobacter pylori (H. pylori)-negative.
- Trial name
- NCT01153659
- Testing
- E3810, Aciphex (rabeprazole), Nexium (esomeprazole)
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Acid Reflux, Gastro Oesophageal Reflux Disease
A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions
The purpose of this study is to assess the effectiveness of Zegerid 20mg capsules and powder and Losec 20mg capsules in healthy volunteers under fasting conditions.
- Trial name
- NCT01710995
- Testing
- Zegerid, Losec
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Norgine
Gastro-Oesophageal Reflux Disease
PPI Sequencing Study
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a…
- Trial name
- NCT00384592
- Testing
- Esomeprazole, Physical exam, Pregnancy test if applicable
- Where
- 14 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Heartburn
Efficacy and Safety of Itopride vs Placebo in Heartburn
The purpose of this study is to evaluate the effects of itopride in patients with heartburn.
- Trial name
- NCT00382577
- Testing
- Itopride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Forest Laboratories
Gastric pH Control
Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intragastric Acid Inhibition
The purpose of this study is to determine if magnesium pantoprazole 20 mg twice a day (b.i.d.), maintains gastric pH above 4 during a longer percentage of time than magnesium pantoprazole 40 mg once a day (qd).
- Trial name
- NCT01499693
- Testing
- Magnesium Pantoprazole 20 mg, Magnesium Pantoprazole 40 mg
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Takeda
Functional Dyspepsia
Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to: assess whether the dose of Itopride Hydrochloride 150 mg extended release tablets, taken once daily has a similar…
- Trial name
- NCT06217393
- Testing
- Itopride Hydrochloride 150 mg extended release tablets, Itopride Hydrochloride 50 mg film coated tablets
- Where
- 19 sites in Armenia, Malaysia and 3 more
- Volunteers
- 564 people
- Sponsor
- Abbott
Pulmonary Disease, Chronic Obstructive
A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is Reduced
This is a Phase I study to assess the combined effects of food and suppression of gastric acid secretion on the relative bioavailability of an immediate release (IR) tablet formulation and prototype bioenhanced formulations of…
- Trial name
- NCT01453478
- Testing
- GSK1325756
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ulcers, Duodenal and Gastric
Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fed Conditions
An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study under fed conditions.
- Trial name
- NCT01847417
- Testing
- Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one, Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two, ASA 100 mg tablet
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Familial Adenomatous Polyposis
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
2 Year randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of EPA-FFA gastro resistant capsules in FAP.
- Trial name
- NCT03806426
- Testing
- Eicosapentaenoic acid free fatty acid (EPA-FFA)
- Where
- Italy
- Volunteers
- 204 people
- Sponsor
- S.L.A. Pharma AG
Gastroesophageal Reflux
Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease
The purpose of this study is to asses the pharmacokinetics and safety of dexlansoprazole modified release (MR), once daily (QD), in adolescent subjects (age 12-17 years old) with Symptomatic Gastroesophageal Reflux Disease.
- Trial name
- NCT00847210
- Testing
- Dexlansoprazole MR
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Takeda
Gastroparesis
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
The purpose of this study is to assess the pharmacodynamic effects (gastric emptying), safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic patients with gastroparesis.
- Trial name
- NCT00861809
- Testing
- GSK962040 25 mg, GSK962040 50 mg, GSK962040 1250 mg
- Where
- 2 sites in Belgium, Sweden
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Gastric Ulcer
An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium
This study is being done to see if Nexium I.V. can reduce and control stomach acid in mechanically ventilated, critically ill patients in an Intensive Care Unit setting.
- Trial name
- NCT00428701
- Testing
- Esomeprazole Sodium
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Reflux Oesophagitis
Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States
The objectives of the study were: To compare a single dose of YF476 at 3 dose levels, placebo and ranitidine with respect to their effects on basal- and food- stimulated gastric pH in healthy volunteers.
- Trial name
- NCT01538797
- Testing
- YF476, Ranitidine
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.